2023

December 7, 2023

EnGeneIC granted FDA Fast-Track Designation for Novel Armed Nanocell Drug Conjugate Pancreatic Cancer Therapeutic.

November 26, 2023

EnGeneIC's promising results in 17 pancreatic ductal adenocarcinoma patients clinical trial published in Clinical Cancer Research.

November 8, 2023

EnGeneIC's advanced metastatic pancreatic ductal adenocarcinoma patient makes full recovery.

January 31, 2023

EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal.

2022

October 14, 2022

EnGeneIC has won the 2022 Australian Financial Review BOSS Prestigious Award for the most Innovative company in Healthcare (Australia and New Zealand)

June 27, 2022

Channel 9 News – 27^th July 2022

2021

September 07, 2021

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

March 26, 2021

EnGeneIC Announces Board Appointment - Professor Bryan Williams

Feb 23, 2021

Worldwide Business - kathy ireland interviews Jennifer MacDiarmid

2020

August 11, 2020

EnGeneIC Announces Board Appointment - Dr. Mark Levitt

June 01, 2020

Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020

March 16, 2020

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

February 12, 2020

EnGeneIC Novel Oncology-Focused Nanotechnology Featured in InsightsCare The 10 Most Innovative Healthcare Nanotech Companies to Watch

2019

December 18, 2019

Winner in Drug Delivery Technology category by Fierce Innovation Awards – Life Sciences Edition 2019

August 8, 2019

EnGeneIC Wins Australian Financial Review Innovation Awards as most Innovative company in healthcare in Australia and New Zealand

May 9, 2019

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1-2a Clinical Study

2018

March 1, 2018

EnGeneIC Announces Publication of Preclinical Data Highlighting Potential Efficacy of EGFR-Targeted EDV(TM) Nanocells to Treat Pediatric Neuroblastoma

2017

September 5, 2017
EnGeneIC Announces Publication in The Lancet Oncology of First Clinical Study Employing EDV™ Nanocell Platform to Enable microRNA Replacement Therapy

March 21, 2017
EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

March 2, 2017
EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme

2016

2016
Cancer breakthrough: Sydney scientists record ‘near complete elimination’ in male mesothelioma patient, similar results in dogs

October 9, 2016
EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology

October 3, 2016
EnGeneIC’s Joint-CEO and Co-Founder, Jennifer MacDiarmid, Ph.D., Recognized in Innovation Category in The Australian Financial Review and Westpac 100 Women of Influence Awards for 2016

April 7, 2016
EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE

April 6, 2016
EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016.

March 10, 2016
EnGeneIC receives Science Meets Business Top 25 Australian R&D spin-off companies award.

January 25, 2016
EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion

January 5, 2016
EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference

2015

November 11, 2015
EnGeneIC Ltd. to Present at the Stifel 2015 Healthcare Conference

October 15, 2015
EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum

September 16, 2015
EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients

August 19, 2015
EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors

August 6, 2015
Indian Link – In-gene-ious!

June 23, 2015
EnGeneIC Recognized as One of the Most Innovative Organizations in Australia at the 2015 Thomson Reuters Australian Citation & Innovation Awards

June 22, 2015
Sky News – Nanotech trial early success

June 15, 2015
EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients

April 16, 2015
Globe Newswire – Foundation for Sarcoidosis Research Announces First New York Fundraiser With Support of EnGeneIC

February 4, 2015
EnGeneIC to Present at BIO CEO & Investor Conference 2015

January 6, 2015
EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor

2014

November 10, 2014
EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma

September 15, 2014
EnGeneIC Named a Recipient of the Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research

August 11, 2014
EnGeneIC Receives Patent from the USPTO for EDV™ Nanocell Technology

June 24, 2014
EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology

2012

November 8, 2012
European CanCer Organisation – First trial in humans of “minicells”: a completely new way of delivering anti-cancer drugs

November 15, 2012
Cancer Discovery – “Minicells” Safely Deliver Targeted Drugs

August 15, 2012
Tenterfield Star – Upclose: Dr Jennifer MacDiarmid

May 8, 2012
Blue Mountains Gazette – Hitting cancer for six

April 26, 2012
Australian Financial Review – Unique technique brings pets back from death’s door

January 26, 2012
AusBiotech Update – A promise to a dying friend turns to a quest for a cure

2009

June 28, 2009
New York Times – New Cancer Treatment Shows Promise in Testing

June 29, 2009
Cosmos Magazine – Killer ‘minicells’ fight drug-resistant cancer

2007

May 7, 2007
New Scientist – ‘Mini-cells’ could stop side-effects of chemotherapy

August 8, 2007
Australian Story – For the Holy Grail